About the Program:
Program Overview:
The Southern United States experiences the greatest burden of HIV infection, illness, and deaths of any U.S. region, and lags in providing quality HIV prevention and care to all its citizens. To address these issues, we have developed a case-based CME program that explores and analyzes the demographics, epidemiology, risk factors, and treatment needs of patients with HIV infection in this region of the US.
This program including the online video discussion and clinically applicable live program series is expected to increase clinician awareness of various issues with HIV care in the Southern US and offer solutions for addressing barriers in such areas as HIV prevention, HIV testing, linkage to care, adherence, and continuation in care.
Target Audience:
This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HIV infection.
Learning Objectives:
Upon completion of the program, participants should be able to:
- Encourage patients to test for HIV infection to increase levels of identification of HIV infected patients
- Provide individualized and effective ARV therapy to treatment-naïve patients with HIV infection
- Apply knowledge and skills for selecting the most effective ARV therapy for treatment-experienced patients
- Address treatment barriers in the treatment of HIV-positive patients in the South, including cultural issues, substance abuse, and co-morbid conditions
- Manage ARV therapy in a variety of patients to address complex medical issues in patients with HIV in the South
Release Date: May 6, 2020
Expiration Date: May 6, 2021
Estimated time to complete each Module: 15 - 45 minutes
Media: Internet
Computer System Requirements: Internet Connection and Browser
Faculty:
Joseph Eron, MD
Professor of Medicine, School of Medicine
Chief, Division of Infectious Diseases
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Helena Kwakwa, MD, MPH
Director HIV Clinical Services
Philadelphia Department of Public Health
Ambulatory Health Services
Philadelphia, Pennsylvania
Richard A. Elion, MD
Associate Professor of Clinical Medicine
George Washington University Medical Center
Washington, DC
David A. Wohl, MD
Professor
Division of Infectious Diseases
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Back to Top
Joint Accreditation Statement:
|
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
|
Back to Top
Credit Designation:
Module 1 (COVID-19 and HIV in the South Panel Discussion):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 2 (Bernadette - Treatment-Experienced/Switching ARVs):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 3 (Antonio - Prevention/Rapid Initiation):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 4 (Miguel - Hospitalized with an OI):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 5 (Rochelle - HIV and Pregnancy):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 6 (AIDS 2020 Update):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 7 (COVID-19 and HIV in the South Panel Discussion - August 2020):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Back to Top
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) requires instructors,
planners, managers and other individuals who are in a position to
control the content of this activity to disclose any real or apparent
conflict of interest (COI) they may have as related to the content of
this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners with
high quality CME activities and related materials that promote
improvements or quality in healthcare and not a specific proprietary
business interest of a commercial interest.
The faculty reported the following financial relationships
or relationships to products or devices they or their spouse/life
partner have with commercial interests related to the content of this
CME activity:
Joseph Eron, MD:
- Consulting Fees: Gilead, ViiV, Merck
- Contracted Research: Gilead, ViiV, Janssen
|
Helena Kwakwa, MD:
- Contracted Research: ViiV
|
Richard Elion, MD:
- Consulting Fees: Gilead, ViiV
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents: Gilead, ViiV
|
David Wohl, MD:
- Consulting fee: Gilead, ViiV, Janssen, Merck
- Contracted Research (to institution): Gilead, ViiV, Merck
|
The planners and managers reported the following financial relationships
or relationships to products or devices they or their spouse/life
partner have with commercial interests related to the content of this
CME activity:
The PIM planners and managers have nothing to disclose.
Back to Top
Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period, May 6, 2020 through May 6, 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.
If
you wish to receive acknowledgment for completing this activity, please
complete the evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 15181. Upon registering and successfully completing the activity evaluation, your certificate
will be made available immediately.
Back to Top
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications.
The opinions expressed in the educational activity are those of the
faculty and do not necessarily represent the views of the planners.
Please refer to the official prescribing information for each product
for discussion of approved indications, contraindications, and warnings.
Back to Top
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
Back to Top
Computer System Requirements
This
program requires a modern web browser (Internet Explorer 7+, Mozilla
Firefox, Apple Safari, Google Chrome). Certain educational activities
may require additional software to view multimedia, presentation, or
printable version of their content. These activities will be marked as
such and will provide links to the required software. That software may
be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint,
Windows Media Player and Real Networks Real One Player.
Back to Top
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs
Jointly provided by the Postgraduate Institute for Medicine and ViralEd, Inc.
|